White Paper

Fc-fusion Cell Line Development: Expression And Analytical Strategies

By Leon Pybus, Fay Saunders, Devika Kalsi, Jeffrey Keen, Jessica Kane-Fidgeon, Daniel Sharkey, Yuta Murakami, Tatsuya Matsuura, Kenta Seko

GettyImages-1288118586 cell development

Following the clinical and commercial success of monoclonal antibodies, Fc-based therapies have captured substantial attention in the biopharmaceutical industry; however, their inherent complexity continues to present manufacturability challenges in both upstream and downstream processes. We describe high titer expression of Fc-fusion proteins using FUJIFILM Diosynth Biotechnologies’ Apollo™ X platform coupled with integrated quality assessments, enhancing our support for clients through the predicted growth in Fc-fusion clinical applications.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online

FUJIFILM Diosynth Biotechnologies